Mireille Ermens

Clinical development consumes 60 to 80 percent of total R&D spend in most biopharma companies. My feasibility and operational leadership background, allows you to:

- Assess whether a development plan is fundable and executable, not just scientifically attractive

- Challenge and pressure test timelines, country mix, site strategy, and enrolment assumptions impacting cost

- Identify hidden cost drivers early such as rare disease recruitment, protocol complexity, and vendor fragmentation

Hence, For clinical-stage companies, time equals valuation. My expertise enables the board to:

- Evaluate whether management timelines are credible

- Understand the operational path to key value inflection points (IND, FPI, interim readouts, BLA/MAA)

- Quantify the impact of delays on cash burn and dilution